These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17293390)

  • 21. Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
    Albanell J; Andreu X; Calasanz MJ; Concha A; Corominas JM; García-Caballero T; López JA; López-Ríos F; Ramón y Cajal S; Vera-Sempere FJ; Colomer R; Martín M; Alba E; González-Martín A; Llombart A; Lluch A; Palacios J
    Clin Transl Oncol; 2009 Jun; 11(6):363-75. PubMed ID: 19531451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
    Hanna W; Nofech-Mozes S; Kahn HJ
    Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromogenic in situ hybridization for the detection of HER-2/neu gene amplification in breast cancer with an emphasis on tumors with borderline and low-level amplification: does it measure up to fluorescence in situ hybridization?
    Bhargava R; Lal P; Chen B
    Am J Clin Pathol; 2005 Feb; 123(2):237-43. PubMed ID: 15842048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
    Ross JS
    Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing.
    Kay E; O'Grady A; Morgan JM; Wozniak S; Jasani B
    J Clin Pathol; 2004 Nov; 57(11):1140-4. PubMed ID: 15509672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
    Mass RD; Press MF; Anderson S; Cobleigh MA; Vogel CL; Dybdal N; Leiberman G; Slamon DJ
    Clin Breast Cancer; 2005 Aug; 6(3):240-6. PubMed ID: 16137435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
    Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
    J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment.
    Kell MR; Power CP
    BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293849
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
    Chan A; McGregor SR
    Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER 2 status in invasive breast cancer: immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
    Shirsat HS; Epari S; Shet T; Bagal R; Hawaldar R; Desai SB
    Indian J Pathol Microbiol; 2012; 55(2):175-9. PubMed ID: 22771638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 testing: the patent "genee" is out of the bottle.
    Goldman B
    CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
    [No Abstract]   [Full Text] [Related]  

  • 35. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
    Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
    Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long non-coding RNA chromogenic in situ hybridisation signal pattern correlation with breast tumour pathology.
    Zhang Z; Weaver DL; Olsen D; deKay J; Peng Z; Ashikaga T; Evans MF
    J Clin Pathol; 2016 Jan; 69(1):76-81. PubMed ID: 26323944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
    Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
    Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
    Short SM; Yoder BJ; Tarr SM; Prescott NL; Laniauskas S; Coleman KA; Downs-Kelly E; Pettay JD; Choueiri TK; Crowe JP; Tubbs RR; Budd TG; Hicks DG
    Breast J; 2007; 13(2):130-9. PubMed ID: 17319853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bright field in-situ hybridization for delineation of HER2 status in breast cancer].
    Li X; Yang X; Zhang W; Yang M; Huang LP
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):358-60. PubMed ID: 21756839
    [No Abstract]   [Full Text] [Related]  

  • 40. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
    Ricardo SA; Milanezi F; Carvalho ST; Leitão DR; Schmitt FC
    J Clin Pathol; 2007 Sep; 60(9):1001-5. PubMed ID: 17158643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.